Clovis Oncology (CLVS) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Clovis Oncology (CLVS) PT Raised to $74 at RBC Capital
May 9, 2018 8:18 AM EDTRBC Capital raised its price target on Clovis Oncology (NASDAQ: CLVS) to $74.00 (from $73.00) while maintaining an Outperform rating.
Analyst Kennen MacKay commented, "We continue to like CLVS as they launch Rubraca in 2L maintenance OC despite a crowded landscape given a potential... More
